Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

01/22/2018 | 04:27am EDT
French multinational pharmaceutical company SANOFI logo seen at their headquater in Paris

PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases.

Sanofi shares fell 3.4 percent by 0920 GMT, making the stock the worst performer on France's benchmark CAC-40 index and several analysts deemed the deal expensive.

The move comes at a time of renewed interest by large drugmakers in smaller biotech firms and predictions by some experts that 2018 will see a substantial pick-up in mergers and acquisitions.

Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $105 per share in cash, marking a premium of 64 percent to Bioverativ's closing price on January 19.

Bioverativ, a maker of haemophilia drugs, was separated from Biogen Inc early last year.

The agreed transaction marks Sanofi's successful return to deal-making after its failure to land major takeovers in recent years. It is its biggest acquisition since the 2011 takeover of U.S. biotech company Genzyme for around $20 billion.

Sanofi lost out on buying California-based cancer specialist Medivation to Pfizer in 2016, and also missed acquiring Swiss biotech company Actelion, which was bought by Johnson & Johnson last year.

"With Bioverativ, we welcome a leader in the growing haemophilia market," Sanofi Chief Executive Olivier Brandicourt said.

The market dealing with treatments for haemophilia is an important one that is evolving rapidly as new drugs change the landscape. Further ahead, gene therapy promises to disrupt traditional approaches to tackling the inherited condition.

Sanofi said the sector had around $10 billion in annual sales, dealing with 181,000 people affected worldwide. It added that haemophilia represented the largest market for rare diseases and was set to grow by more than 7 percent per year through to 2022.


Sanofi expects the acquisition to be immediately accretive to its business earnings per share in the full 2018 financial year and up to 5 percent accretive for the following year.

However, some analysts questioned the cost.

"Bioverativ looks a relatively expensive acquisition. It is logical in terms of building around Sanofi's presence and pipeline in rare diseases and haemophilia, though management may have to argue against concerns on competition," analysts with Jefferies wrote in a note to clients.

"The obvious parallel is Shire's highly unpopular acquisition of Baxalta; but Sanofi's 2011 acquisition of rare disease specialist Genzyme was also unpopular at the time, yet has it turned into a major success story," analysts with Kepler said.

Sanofi added it would fund the takeover with a mixture of existing cash resources and a debt issue.

"We have the means to make further takeovers," added Brandicourt on a conference call, without going into further details.

Brandicourt has said in the past he was ready to do deals of a similar size to the $20 billion purchase of Genzyme to help accelerate growth at France's biggest drugmaker. One asset analysts and bankers believe could be of interest is Pfizer's consumer health unit, although competition for this business is likely to be fierce.

Sanofi said it expected to achieve a return on its invested capital (ROIC) in excess of the cost of capital within three years. The French group also expects to preserve its strong credit rating.

This month Celgene agreed to pay up to $7 billion to take over Impact Biomedicines and the U.S. company is also said to be circling Juno Therapeutics.

In Europe, Novo Nordisk has offered $3.1 billion for Ablynx and Japan's Takeda Pharmaceutical plans to buy TiGenix for $630 million.

The spate of deal-making follows a relatively subdued 2017 for biotech M&A.

Lazard advised Sanofi on the deal, while Guggenheim Securities and J.P. Morgan advised Bioverativ.

(Additional reporting by Ben Hirschler in London, Laurence Frost and Matthias Blamont in Paris, and Shubham Kalia in Bengaluru; editing by Jason Neely and Keith Weir)

By Sudip Kar-Gupta

ę Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 0.61% 333.96 Delayed Quote.36.39%
CHANGE INC. -0.48% 2684 End-of-day quote.-23.86%
JASON CO., LTD. 0.75% 539 End-of-day quote.-19.31%
JOHNSON & JOHNSON 0.46% 172.66 Delayed Quote.9.71%
JPMORGAN CHASE & CO. -0.13% 151.45 Delayed Quote.19.19%
JUST GROUP PLC 1.66% 98.2 Delayed Quote.38.20%
LAND CO., LTD. -8.33% 11 End-of-day quote.37.50%
LAZARD LTD -2.06% 43.22 Delayed Quote.2.17%
NOVO NORDISK A/S 0.21% 562.2 Delayed Quote.31.49%
PFIZER, INC. 0.69% 42.1 Delayed Quote.14.37%
SANOFI -0.53% 87.12 Real-time Quote.10.70%
SWISS RE LTD -0.07% 83.68 Delayed Quote.0.48%
All news about BIOGEN INC.
02:03pSTREET COLOR : Biogen Reportedly Pulls Alzheimer Drug Aduhelm Paper After Jama D..
01:54pBIOGEN : withdrew Aduhelm paper after JAMA asked for edits - Axios
08:38aBIOGEN : Canaccord Genuity Adjusts Biogen's Price Target to $423 From $359, Reit..
07/26BIOGEN : Ionis Report 'Positive' Alzheimer's Treatment Data From Phase 1b Trial
07/26BIOGEN : and Ionis report positive topline clinical data on investigational Alzh..
07/26Biogen Inc. and Ionis Pharmaceuticals, Inc. Announces Positive Topline Clinic..
07/26BIOGEN : and Eisai Announce ADUHELM™á(aducanumab-avwa) Data Presentations ..
07/26BIOGEN : Reduction in Biomarkers of Alzheimer's Disease Pathophysiology Followin..
07/26BIOGEN : Subgroup Analyses of the Amyloid PET Substudies from EMERGE and ENGAGE,..
07/26BIOGEN : Item-level Analysis of Clinical Measures in Patients with Early Symptom..
More news
Financials (USD)
Sales 2021 10 769 M - -
Net income 2021 2 039 M - -
Net Debt 2021 1 486 M - -
P/E ratio 2021 24,5x
Yield 2021 -
Capitalization 49 771 M 49 771 M -
EV / Sales 2021 4,76x
EV / Sales 2022 4,34x
Nbr of Employees 9 100
Free-Float 84,9%
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 333,96 $
Average target price 418,86 $
Spread / Average Target 25,4%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors